RGLS News and Press, Regulus Therapeutics Inc. From 03/12/24

2024-03-12 08:38:03 ET Regulus Therapeutics ( NASDAQ: RGLS ) shares rose 68.84% at $2.33  after it entered into a securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. Under the securities p...

2024-03-12 07:48:27 ET DENVER, Colo., Mar 12, 2024 ( 247marketnews.com )- Regulus Therapeutics Inc. (NASDAQ: RGLS ) reported, this morning, positive topline results from the second cohort of patients in its Phase 1b MAD double-blind, placebo-controlled study of RGLS8429 for the trea...

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity PR Newswire SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovat...

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Mechanistic dose response obse...

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire SAN DIEGO , Jan. 2, 2024 ...

2023-12-27 16:26:14 ET More on Regulus Therapeutics Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regulus Therapeutics For further details see: Regulus Therapeutics ...

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of i...

2023-11-10 11:06:49 ET More on Regulus Therapeutics Regulus posts early Phase 1 data for lead asset in kidney disease Seeking Alpha’s Quant Rating on Regulus Therapeutics Historical earnings data for Regulus Therapeutics Financial information for Regul...

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates PR Newswire Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant P...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...